These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29310421)

  • 1. Assessment of change in glucose metabolism in white matter of amyloid-positive patients with Alzheimer disease using F-18 FDG PET.
    Jeong YJ; Yoon HJ; Kang DY
    Medicine (Baltimore); 2017 Dec; 96(48):e9042. PubMed ID: 29310421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition.
    Baghel V; Tripathi M; Parida G; Gupta R; Yadav S; Kumar P; Dey AB; Damle NA; Kumar R; Bal C
    Clin Nucl Med; 2019 Nov; 44(11):e597-e601. PubMed ID: 31584490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease.
    Takahashi R; Ishii K; Yokoyama K; For The Alzheimer S Disease Neuroimaging Initiative EY
    Curr Alzheimer Res; 2017; 14(2):161-168. PubMed ID: 27334941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A deep learning model for generating [
    Sanaat A; Boccalini C; Mathoux G; Perani D; Frisoni GB; Haller S; Montandon ML; Rodriguez C; Giannakopoulos P; Garibotto V; Zaidi H
    Eur J Nucl Med Mol Imaging; 2024 Oct; 51(12):3518-3531. PubMed ID: 38861183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
    Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
    Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
    Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
    Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
    Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
    Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
    J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.
    Lee JY; Lee H; Yoo HB; Choi JS; Jung HY; Yoon EJ; Kim H; Jung YH; Lee HY; Kim YK
    Neurotherapeutics; 2019 Apr; 16(2):394-403. PubMed ID: 30761509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease.
    Sintini I; Schwarz CG; Martin PR; Graff-Radford J; Machulda MM; Senjem ML; Reid RI; Spychalla AJ; Drubach DA; Lowe VJ; Jack CR; Josephs KA; Whitwell JL
    Hum Brain Mapp; 2019 Apr; 40(5):1618-1631. PubMed ID: 30549156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.
    Schilling LP; Pascoal TA; Zimmer ER; Mathotaarachchi S; Shin M; de Mello Rieder CR; Gauthier S; Palmini A; Rosa-Neto P;
    Mol Neurobiol; 2019 Jul; 56(7):4916-4924. PubMed ID: 30414086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients.
    Zhou Y; Yu F; Duong TQ;
    J Magn Reson Imaging; 2015 Jan; 41(1):102-9. PubMed ID: 24382798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coupled Imaging with [
    Chiaravalloti A; Castellano AE; Ricci M; Barbagallo G; Sannino P; Ursini F; Karalis G; Schillaci O
    Mol Imaging Biol; 2018 Aug; 20(4):659-666. PubMed ID: 29404839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.
    Ziolko SK; Weissfeld LA; Klunk WE; Mathis CA; Hoge JA; Lopresti BJ; DeKosky ST; Price JC
    Neuroimage; 2006 Oct; 33(1):94-102. PubMed ID: 16905334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.